Diseases
> Pneumococcal
Reporting
Invasive Pneumococcal Disease in Children <5 Years Who Have Received
Pneumococcal Conjugate Vaccine
In October 2000, the Advisory Committee
on Immunization Practices (ACIP) and the American Academy of Pediatrics
(AAP) recommended the use of PCV7 (7-valent, pneumococcal polysaccharide-protein
conjugate vaccine, PrevnarTM) among all children aged 2-23 months
and for children aged 24-59 months who are at increased risk for
pneumococcal disease (e.g., children with sickle cell disease, human
immunodeficiency virus infection, and other immunocompromising or
chronic medical conditions). Since PCV7 was licensed for use, CDC
has received several reports of invasive pneumococcal disease among
infants and children who had received at least one dose of PCV7.
Cases following vaccination are to
be expected, since vaccine efficacy was 97% for invasive disease
with pneumococcal serotypes included in the vaccine and 89% for
all serotypes.
In order to monitor vaccine issues,
the Respiratory Diseases Branch (RDB) at CDC has developed a tracking
system to determine the serotype of these invasive pneumococcal
isolates, record host conditions that may contribute to PCV7 failure,
and monitor for vaccine lots that may be associated with decreased
protection. We will limit cases to children less than five years
of age with invasive pneumococcal infections who have received at
least one dose of PCV7. This tracking system is consistent with
the 2000 CSTE position statement on invasive pneumococcal disease,
which recommends that invasive pneumococcal disease in children
less than 5 years old be placed under national surveillance. The
position statement can be reviewed on the Council for State and
Territorial Epidemiologists (CSTE) web page (http://www.cste.org/ps/2000/2000-id-06.htm).
Please use the instruction
sheet and the supplemental case report
form. When a child <5 years of age who has received at least
one dose of PCV7 is diagnosed with invasive pneumococcal disease,
defined as the isolation of S. pneumoniae from a normally sterile
site (e.g., CSF, blood, joint fluid, pleural fluid), we ask that
a PCV7 failure case report form be completed and sent along with
the isolate and form CDC 50.34 (CDC
lab report form) through the State Health Department to the
Streptococcus laboratory, Respiratory Diseases Branch, CDC. Cases
of suspected PCV7 failure may also be reported to the Vaccine Adverse
Events Reporting System (VAERS), though reporting such cases is
not required. However, if a clinically significant adverse event
occurs after immunization with PCV7, it should be reported to VAERS
(http://www.vaers.org).
We are grateful for your assistance
in collecting these isolates and the clinical information. We expect
that the actual number of reports for any one state will be small.
For questions, call:
Duty Officer
Respiratory Diseases Branch, C23
Centers for Disease Control and Prevention
1600 Clifton Road, Atlanta, GA 30333
(404) 639-2215
Links
to forms and instruction sheet |
HTML |
|
Text* |
Pneumococcal
conjugate vaccine failure case report form |
| .pdf
version |
|
CDC
lab report form |
|
|
|
Instruction
sheet |
.htm
version |
| |
* The text version is provided for
those that require text-only documents for screen-reader devices.
Please contact NIPINFO@cdc.gov via email, if you need any additional
files in text-only format.
|